TITLE

FTC comes down on the side of generics

AUTHOR(S)
Zwillich, Todd
PUB. DATE
October 2002
SOURCE
Drug Topics;10/7/2002, Vol. 146 Issue 19, p66
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on reactions of drugmakers and consumer groups to the news that federal trade regulators are urging the U.S. Congress to pass a law that could shift the prescription drug market away from brand-name pharmaceutical toward lower-cost generics. Debate over rising prices of prescription drugs and whether to add a prescription drug benefit to the federal Medicaid program. INSET: GPOs: Another subject under FTC scrutiny..
ACCESSION #
7689813

 

Related Articles

  • Rx makers want Medicaid rebate refunds.  // Drug Topics;12/9/96, Vol. 140 Issue 23, p7 

    Reports on government inspection of recalculations made by American pharmaceutical firms on their average prices. Use of average prices as basis for Medicaid rebates; Requirement of retroactive adjustments in favor of the manufacturers.

  • Iowa Pool to Lower Medicaid Drug Costs.  // Policy & Practice (19426828);Sep2006, Vol. 64 Issue 3, p28 

    The article reports on the collaboration of Iowa, Maine and Vermont to negotiate lower prices for the drugs they procure for Medicaid beneficiaries. Iowa Governor Tom Vilsack is planning to save about $11 million every year in the said move. The group of states expect to get pharmaceutical...

  • Courting Big PhRMA. Buntin, John // Governing;Apr2003, Vol. 16 Issue 7, p65 

    Reports on the attempts of U.S. state governments to reduce drug prices in their jurisdictions as of April 2003. Status of the attempts of Maine to pressure drug companies to extend low Medicaid prices for medications to certain non-Medicaid recipients; Approval of the drug-price reduction plan...

  • Medicaid cuts make serving the poor bad business. Eder, Rob // Drug Store News;11/21/2005, Vol. 27 Issue 16, p14 

    The article comments on the impact of the Medicaid Reform package on the pharmaceutical industry. The article discussed losses in prescription drugs. Cuts will soften pharmacy margins. The amount of discount given to manufacturers was also discussed.

  • Pharmacy Could Lose Medicaid Margins. Toth, Wendy // SN: Supermarket News;1/1/2007, Vol. 55 Issue 1, p18 

    The article focuses on the possibility of lower margins facing retail pharmacy as a result of the proposed cuts to Medicaid reimbursement by the U.S. Centers for Medicare and Medicaid Services. According to Ty Kelly, director of government relations for the Food Marketing Institute, many...

  • Florida investigates generic pricing practices.  // Drug Store News;8/23/2004, Vol. 26 Issue 10, p56 

    Reports on Florida Attorney General Charlie Crist's issuance of civil subpoenas to six generic drug makers regarding their wholesale pricing practices since 1994, with allegations of overcharging the state Medicaid program. Request for materials to help the state determine liability under the...

  • Pharma Industry urges Review of Maine Drug Law.  // Chemical Market Reporter;6/11/2001, Vol. 259 Issue 24, p28 

    Reports on the appeal of the pharmaceutical industry before the United States Court of Appeals for the First Circuit to review a decision upholding Maine's prescription drug price control law. Arguments of the Pharmaceutical Research and Manufacturers Association (PhRMA) against the decision;...

  • Prescription Drugs: Oversight of Drug Pricing in Federal Programs: GAO-07-481T.  // GAO Reports;2/9/2007, p1 

    Several federal programs help pay for or reduce the costs of prescription drugs for eligible individuals and entities. Three examples are the Medicaid drug rebate program, part of the joint federal-state Medicaid program that finances medical services for certain low-income people; the 340B...

  • Pharmaceutical industry battling losses internally and in court. Wylot, Robert // Warsaw Business Journal;4/22/2002, Vol. 8 Issue 16, p3 

    Reports the changes in drug regulatory prices in Poland. Lack of transition period; Decrease in the prices of foreign-made drugs; Authority in suing the government of companies affected by the lack of transition period.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics